International journal of molecular sciencesAlzheimer DiseaseHumansAmyloid beta-PeptidesImmunizationPassive
FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?
Martin Higgins, Veronica Wasef, Andrea Kwakowsky
Published: 202610.3390/ijms27020883
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and blood-brain barrier (BBB) dysfunctio…
Preview only. Read the full abstract at the source